Skip Nav Destination
Issues
1 February 2015
-
Cover Image
Cover Image
Reticker-Flynn and Bhatia found that tumor-derived IL6 induced CD11b+-galectin-3+ leukocyte mobilization from the bone marrow in a mouse model of lung adenocarcinoma. Metastatic cell lines and human non–small cell lung cancer samples exhibited increased surface presentation of the galectin-3 ligand, Thomsen-Friedenreich Antigen (T-Antigen). Elevated T-Antigen surface presentation was mediated by altered expression of the glycosyltransferases C2GnT2 and St6GalNAc4, which prevented T-Antigen glycan elongation. Restoration of T-Antigen glycan chain elongation decreased T-Antigen presentation, reduced tumor-cell galectin-3 binding, and inhibited experimental metastases in vivo. These results indicate that aberrant glycosyltransferase activities play a critical role in the early metastatic niche to promote metastatic progression of lung tumors. For details, please see the article by Reticker-Flynn and Bhatia on page 168. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
In This Issue
In the Spotlight
Prospective
Review
Research Briefs
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
Sarah L. Sawyer; Lei Tian; Marketta Kähkönen; Jeremy Schwartzentruber; Martin Kircher; University of Washington Centre for Mendelian Genomics; FORGE Canada Consortium; Jacek Majewski; David A. Dyment; A. Micheil Innes; Kym M. Boycott; Lisa A. Moreau; Jukka S. Moilanen; Roger A. Greenberg
Research Articles
Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map
Maria M. Martins; Alicia Y. Zhou; Alexandra Corella; Dai Horiuchi; Christina Yau; Taha Rakhshandehroo; John D. Gordan; Rebecca S. Levin; Jeff Johnson; John Jascur; Mike Shales; Antonio Sorrentino; Jaime Cheah; Paul A. Clemons; Alykhan F. Shamji; Stuart L. Schreiber; Nevan J. Krogan; Kevan M. Shokat; Frank McCormick; Andrei Goga; Sourav Bandyopadhyay
News in Brief
Research Watch
Autophagy
Bladder Cancer
Breast Cancer
Clinical Trials
DNA Repair
Drug Resistance
Epigenetics
Immunotherapy
Medulloblastoma
Melanoma
Metastasis
Targeted Therapy
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.